Resmetirom for Nonalcoholic Steatohepatitis (NASH)

Resmetirom ( Rezdiffra ) is set to become the first medication approved for treating nonalcoholic steatohepatitis (NASH) with fibrosis in adults . About 5% of adults in the US have NASH. You will start to hear NASH called metabolic dysfunction-associated steatohepatitis (MASH) to reflect its link with cardiometabolic risk factors (diabetes, dyslipidemia, obesity, etc…